[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-362334-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-362334-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","association-of-hmgb1-expression-with-prognosis-of-non-small-cell-lung-cancer-a-systematic-review-and-meta-analysis","Association of HMGB1 expression with prognosis of non-small cell lung cancer - a systematic review and meta-analysis","","The prognostic value of high mobility group box 1 (HMGB1) expression in non-small cell lung cancer (NSCLC) remains uncertain. This systematic review and meta-analysis evaluates whether HMGB1 expression levels relate to NSCLC survival outcomes through pooled hazard ratios. Studies were identified from major databases up to September 18, 2025, with independent extraction and quality appraisal. Overall results show no significant association with overall survival, while subgroup findings suggest context-dependent prognostic effects.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/association-of-hmgb1-expression-with-prognosis-of-non-small-cell-lung-cancer-a-systematic-review-and-meta-analysis/362334/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/association-of-hmgb1-expression-with-prognosis-of-non-small-cell-lung-cancer-a-systematic-review-and-meta-analysis/362334.png","ImageObject",300,407,{"name":42,"@type":43},"Margaret","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-07","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What question does the meta-analysis address about HMGB1 and NSCLC?","Question",{"text":63,"@type":64},"It evaluates whether HMGB1 expression levels are associated with NSCLC prognosis, using survival outcomes aggregated across eligible studies.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were studies selected and assessed for quality?",{"text":68,"@type":64},"Databases including Embase, the Cochrane Library, Web of Science, and PubMed were searched until September 18, 2025. Two reviewers independently extracted data and appraised quality using the Newcastle-Ottawa Scale.",{"name":70,"@type":61,"acceptedAnswer":71},"What is the main finding regarding overall survival in the overall NSCLC population?",{"text":72,"@type":64},"The pooled hazard ratio for overall survival was not statistically significant (HR 1.08, 95% CI 0.91–1.29, P=0.356), indicating no clear overall prognostic association.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},362334,1790845293,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},137451207643,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Zheng et al. BMC Cancer (2026) 26:184 BMC Cancer  \n[https://doi.org/10.1186/s12885-025-15508-8](https://doi.org/10.1186/s12885-025-15508-8)  \nSYSTEMATIC REVIEW Open Access  \nAssociation of HMGB1 expression  \nwith prognosis of non-small cell lung cancer: a systematic review and meta-analysis  \nTing Zheng1*, Xingxing Li1, Jianjiang Jin1 and Li Zhou1  \nAbstract  \nBackground The prognostic significance of high mobility group box 1 (HMGB1) expression in the non-small cell lung cancer (NSCLC) population remains controversial. This study endeavors to systematically evaluate the relation of HMGB1 expression levels to NSCLC prognosis via a comprehensive meta-analysis.  \nMethods Embase, the Cochrane Library, Web of Science, as well as PubMed were retrieved for eligible studies until September 18, 2025. Two reviewers independently extracted relevant data and appraised the study quality. The study quality was examined via the Newcastle-Ottawa Scale (NOS) . Hazard Ratio (HR) with corresponding confidence intervals (CIs) for survival outcomes were calculated and summarized respectively. Subgroup analysis, regression analysis, sensitivity analysis and publication bias were conducted to investigate the findings further.  \nResults 11 studies on 4,527 NSCLC patients were encompassed. All eligible studies had high methodological quality. The pooled HR of OS was 1.08 (95% CI: 0 .91–1. 29, P = 0 . 356), suggesting no significant association of HMGB1 expression levels with NSCLC prognosis. Subgroup analysis of studies with sample sizes \u003C 100 revealed a significant relation of high HMGB1 expression to poorer OS (HR: 1. 51, 95% CI: 1.22–1. 87) . Conversely, when HMGB1 expression  \nlevel was detected before chemotherapy, high HMGB1 expression was linked to improved OS (HR: 0 . 96, 95% CI: 0.93–0. 99) .  \nConclusion This meta-analysis demonstrated that HMGB1 expression was not significantly associated with OS in the overall NSCLC population, but may have context-dependent prognostic value warranting further investigation. Keywords NSCLC, Prognosis, HMGB1, Meta-analysis  \n*Correspondence: Ting Zheng [zz_tt666@163.com](zz_tt666@163.com)  \n1Department of Medical Oncology, The First People’s Hospital of Linping District, Hangzhou, Zhejiang, China  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.0/.)  \nZheng et al. BMC Cancer (2026) 26:184  \nBackground  \nLung cancer is the primary reason behind cancer-linked morbidity and mortality worldwide, with the annual incidence rate of nearly 2.5 million and deaths close to 1.8 million [1]. Non-small cell lung cancer (NSCLC), comprising 80–85% of lung cancers, is the most frequent histological type [2]. Most NSCLC patients are advanced-stage when diagnosed (either locally or distantly metastatic), resulting in poor 5-year survival [3]. Despite tremendous advances in treatment methods like surgery, chemotherapy, radiotherapy, targeted therapy, as ","cbCaibqqdrZxIjsP","https://ap.wps.com/l/cbCaibqqdrZxIjsP","pdf",2639116,14,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Background\n## Clinical need for prognostic biomarkers\n## Biological role of HMGB1","[{\"question\":\"What question does the meta-analysis address about HMGB1 and NSCLC?\",\"answer\":\"It evaluates whether HMGB1 expression levels are associated with NSCLC prognosis, using survival outcomes aggregated across eligible studies.\"},{\"question\":\"How were studies selected and assessed for quality?\",\"answer\":\"Databases including Embase, the Cochrane Library, Web of Science, and PubMed were searched until September 18, 2025. Two reviewers independently extracted data and appraised quality using the Newcastle-Ottawa Scale.\"},{\"question\":\"What is the main finding regarding overall survival in the overall NSCLC population?\",\"answer\":\"The pooled hazard ratio for overall survival was not statistically significant (HR 1.08, 95% CI 0.91–1.29, P=0.356), indicating no clear overall prognostic association.\"}]","Association of HMGB1 expression with prognosis of non-small cell lung cancer - a systematic review and meta-analysis | PDF",1790147164,35,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ac9cbdf7ddaa997c311eddcfc8dcd53a.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b31e138f7fd502005b0c72afede45a18.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e4010ab193ef8ec018684faa114cb4da.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cc71169a78778b9ecd260c0a54f63bf4.webp",980,1306]